Structure Therapeutics is a large accelerated filer reporting a limited operating history with significant operating losses and four product candidates currently in clinical development: aleniglipron, ACCG-2671, ACCG-3535, and LTSE-2578. As of October 31, 2026, the company had 214,771,065 ordinary shares outstanding and expects to require substantial additional capital to fund future operations.
Structure Therapeutics reported third quarter 2026 financial results and provided a corporate update on its oral small molecule obesity portfolio, including the enrollment of its Phase 3 ACCOMPLISH program for aleniglipron. The company ended the quarter with $1.2 billion in cash and investments, which is expected to fund operations through 2028. Topline data from the registrational Phase 3 trials are anticipated in the second half of 2028.
“With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management.”
Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics
“We are also advancing our oral small molecule amylin portfolio by progressing the multiple ascending dose clinical trial of ACCG-2671, preparing to initiate a Phase 1 clinical trial of ACCG-3535 and exploring GLP-1 combination approaches.”
Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics